Newswise — ITHACA, N.Y. – With a desire to inhibit metastasis, Cornell biomedical engineers have found the natural switch between the body’s inflammatory response and how malignant breast cancer cells use the bloodstream to spread. (PLOS ONE, Jan. 23, 2013)
Pro-inflammatory signaling molecules in blood called cytokines constitute a “switch” that induces the mechanism by which breast cancer cells “roll” and adhere to the blood vessel surface. The cancer cells eventually stick to the vessel and infiltrate it.
The laboratory of Michael R. King, Cornell professor of biomedical engineering has developed a flow chamber that mimics an inflamed endothelium (the blood vessel wall) and has used this to investigate the metastatic cascade.
In understanding the adhesive behavior of a particularly metastatic cell line, King and Yue Geng, graduate student in the field of biomedical engineering, discovered unexpectedly that these cells were unable to interact with selectins (receptor sites on the endothelium) – a key step in the metastatic cascade. This mechanism is identical to how white blood cells infiltrate blood vessels to reach the site of inflammation.
Cancer has long been associated with inflammation – the body’s natural defense mechanism – and now the researchers have demonstrated a definitive link. They found that the presence of pro-inflammatory molecules – the cytokines IL-6 and TNF-alpha – enable the malignant, hormone therapy-resistant breast cancer cells used in the study to adhere to the endothelial wall, leading to metastasis.
Before the cancer has spread, tumor cells first encounter IL-6 and TNF-alpha in the primary tumor’s microenvironment. These cytokines induce proliferation and aggregation of cancer cells, triggering other cancer cells to secrete more cytokines, resulting in a positive feedback loop.
The bioengineers went on to design several different cell culture setups to culture cancer cells with human plasma, IL-6 and TNF-alpha to test their hypotheses that inflammatory molecules in blood may induce adhesion capability. All of them promoted breast cancer cell metastatic behavior.
To confirm the results, the scientists used more sophisticated, real-life 3-D tumor spheroids, which are more physiologically accurate. In fact, the spheroid tumor cells exhibited the most significant increase in the interaction between the cancer cells and the blood vessel. They also treated some of the samples with a known anti-inflammatory drug called Metformin, which blocks IL-6, and they found that these samples were not able to metastasize – further accentuating their results.
Improving cancer treatment to fight metastasis via the bloodstream will depend on undoing this roll-and-stick mechanism of cancer cells, Geng says. The Cornell research could form the basis for immunotherapies to block the ligand-selectin binding of cancer cells, by first counteracting the inflammatory cytokines that, it seems, set the whole process in motion.
The paper, “Phenotypic switch in blood: effects of pro-inflammatory cytokines on breast cancer cell aggregation and adhesion,” appears online Jan. 23, 2013 in the open-access, peer-reviewed journal PLOS ONE. The paper’s first author is Geng and the senior author is King. Co-authors include Jong-Wei Hsu, Cornell post-doctoral researcher; Cornell graduate students Siddarth Chandrasekaran and Andrew D. Hughes; and undergraduate student Mishka Gidwani.
The paper is available at:
The National Cancer Institute via the Center on the Microenvironment and Metastasis, and a National Science Foundation Graduate Research Fellowship, funded the research.